Last reviewed · How we verify
LASN01
At a glance
| Generic name | LASN01 |
|---|---|
| Also known as | Low-dose LASN01, High-dose LASN01 |
| Sponsor | Lassen Therapeutics 1 PTY LTD |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease (PHASE2)
- A Study to Evaluate the Safety, Preliminary Efficacy, and Pharmacokinetic Properties of LASN01 in Healthy Subjects and in Patients With Pulmonary Fibrosis or Thyroid Eye Disease (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LASN01 CI brief — competitive landscape report
- LASN01 updates RSS · CI watch RSS
- Lassen Therapeutics 1 PTY LTD portfolio CI